top of page

European Commission approves Revolution Medicines' Rasonque as first broad RAS-targeted therapy for metastatic pancreatic cancer

Writer: nuaxia
nuaxia
1 hour ago
2 min read

The European Commission has authorised Revolution Medicines' Rasonque as an oral broad RAS-targeted treatment for previously treated metastatic pancreatic cancer, marking a significant advance in a disease with substantial unmet medical need.


Revolution Medicines announced on 16 November 2026 that the European Commission had approved Rasonque (daraxonrasib) as once-daily oral monotherapy for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic treatment, including patients with or without an identified RAS tumour mutation.


The authorisation establishes a new targeted treatment option for previously treated metastatic pancreatic cancer and represents a final European Commission regulatory decision rather than a CHMP recommendation, although practical availability across individual European countries will depend on subsequent pricing, reimbursement and market-access arrangements.

Field

Content

Article Type

Approvals

Company

Revolution Medicines

Product Brand Name

Rasonque

Active Ingredient

Daraxonrasib

Drug Classification

Broad RAS-targeted therapy

Drug Modality

Small-molecule targeted medicine

Administration Route

Oral

Dosing Frequency

Once daily

Regulatory Authority

European Commission

Announcement Date

16 November 2026

Regulatory Decision

European Commission marketing authorisation

Regulatory Status

Approved

Geographic Scope

European Union

Therapeutic Area

Oncology

Cancer Type

Pancreatic adenocarcinoma

Disease Stage

Metastatic

Approved Treatment Setting

Following at least one prior systemic therapy

Treatment Regimen

Daraxonrasib monotherapy

Minimum Prior Treatment Requirement

At least one systemic therapy

RAS Mutation Eligibility

Patients with or without an identified RAS tumour mutation

Molecular Target

RAS signalling pathway

First Broad RAS-Targeted Medicine Claim

Described as the first broad RAS-targeted medicine in metastatic pancreatic cancer

Clinical Unmet Need

Limited treatment options in previously treated metastatic pancreatic cancer

European Regulatory Milestone

Final marketing authorisation

CHMP Recommendation Only

No

Country-Level Reimbursement

Subject to national decisions

Immediate Uniform EU Patient Access

Not established

What Happened

The European Commission approved Rasonque for previously treated metastatic pancreatic adenocarcinoma.

Why It Matters

The approval creates a new targeted therapeutic option in a cancer associated with major unmet clinical need.

Clinical Significance

The authorised population includes patients irrespective of whether a RAS tumour mutation has been identified.

Strategic Significance

Represents a major commercial and regulatory milestone for Revolution Medicines' RAS-targeted oncology programme.

Access Significance

Marketing authorisation does not automatically establish reimbursement or availability in every EU member state.

Key Takeaway

Rasonque has received European Commission approval as once-daily oral monotherapy for previously treated metastatic pancreatic cancer.

What to Watch

National reimbursement decisions, European commercial rollout, treatment adoption and additional clinical evidence.

Primary Source

Revolution Medicines

Primary Source URL

https://revmed.gcs-web.com/news-releases/news-release-details/european-commission-approves-revolution-medicines-rasonquer

Submitted Source

GlobeNewswire

Submitted Source URL

https://www.globenewswire.com/news-release/2026/11/16/3404001/0/en/european-commission-approves-revolution-medicines-rasonque-daraxonrasib-the-first-broad-ras-targeted-medicine-in-metastatic-pancreatic-cancer.html

Relevant Date

16 November 2026


Discover how nuaxia can support your next medical education initiative:

Comments

Rated 0 out of 5 stars.
No ratings yet

Add a rating
bottom of page